Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
07:16pm, Monday, 02'nd Jun 2025
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
11:06am, Monday, 02'nd Jun 2025
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
08:41am, Monday, 02'nd Jun 2025
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation,
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
08:00am, Monday, 02'nd Jun 2025
Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
Experimental AstraZeneca pill helps cut risk of breast cancer progression
07:14am, Monday, 02'nd Jun 2025
CNBC's Joe Kernen reports on the latest news.
'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
08:43am, Sunday, 01'st Jun 2025
A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found.
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
08:04am, Sunday, 01'st Jun 2025
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbocic
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
08:06am, Saturday, 31'st May 2025
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t
Danaher Partners With AstraZeneca to Support Precision Medicine
12:51pm, Friday, 30'th May 2025
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
04:30pm, Thursday, 29'th May 2025
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
10:25am, Wednesday, 28'th May 2025
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
11:50am, Tuesday, 27'th May 2025
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
04:50am, Sunday, 25'th May 2025
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2-direc
Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms
08:00am, Thursday, 22'nd May 2025
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.
